Comment from Medical Device Manufacturers Association (MDMA)

Summary: The Medical Device Manufacturers Association (MDMA) supports the FDA's effort to establish a uniform system for classifying protocol deviations in clinical studies. They suggest specific improvements to the draft guidance, including clarifying terminology, refining the categorization of certain deviations, and providing more detailed instructions on data handling and reporting procedures.